Physician profile
Lisa Ferrin
NPI 1841475852
$4,727.92
in general payments reported to CMS, 2019-2025
32 companies · $2,641 in 2025
The $2,641 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $101 · 2022: $175 · 2023: $531 · 2024: $1,279 · 2025: $2,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,451.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $885.84 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Alkermes, INC. | $517.82 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $514.49 | 2021-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Lundbeck LLC | $319.68 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Neurocrine Biosciences, INC. | $312.71 | 2023-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $277.69 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $252.02 | 2024-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $236.73 | 2023-2024 | Aptiom |
| Jazz Pharmaceuticals INC. | $186.45 | 2025 | |
| Indivior INC. | $171.72 | 2022-2025 | Sublocade, Perseris |
| Abbvie INC. | $155.27 | 2024-2025 | |
| Corium, LLC | $120.44 | 2024-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $114.64 | 2022-2025 | Invega Sustenna, Spravato |
| Noven Therapeutics, LLC | $109.73 | 2023-2025 | Secuado, Xelstrym |
| Harmony Biosciences LLC | $74.01 | 2023-2025 | Wakix |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $61.36 | 2021 | |
| Vanda Pharmaceuticals INC. | $51.86 | 2022 | |
| Almatica Pharma LLC | $42.19 | 2022-2023 | Gralise, Loreev Xr |
| Lilly USA, LLC | $38.99 | 2024-2025 | Zepbound, Mounjaro |
| Kerecis Limited | $29.12 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Idorsia Pharmaceuticals US INC | $28.11 | 2023-2024 | Quviviq |
| Hartmann USA, INC. | $25.59 | 2025 | Zetuvit Plus 10x10 P10 |
| Bioxcel Therapeutics, INC. | $24.03 | 2023 | Igalmi |
| Azurity Pharmaceuticals, INC. | $23.33 | 2025 | Horizant |
| Mylan Specialty L.P. | $22.82 | 2021 | |
| Luye Pharma (USA) LTD. | $20.71 | 2025 | Erzofri Extended-Release |
| Novo Nordisk INC | $20.60 | 2023 | Ozempic, Rybelsus |
| Ardelyx, INC. | $19.24 | 2024 | Ibsrela |
| Reprise Biomedical, INC. | $18.47 | 2025 | Miro 3d |
| Averitas Pharma INC. | $18.36 | 2025 | Qutenza |
| E.R. Squibb & Sons, L.L.C. | $17.50 | 2025 | Cobenfy |
| Uswm, LLC | $16.40 | 2024 | Lucemyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Ferrin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.